Literature DB >> 2362911

Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation.

L Gu1, R G Strickley, L H Chi, Z T Chowhan.   

Abstract

The drug-excipient incompatibility screen for moexipril hydrochloride (1) using various isothermal stress methods is reported herein. It was found that most of the commonly used filters, disintegrants, lubricants, glidants, and coating agents were incompatible with 1 in dry powder mixtures; moisture and basic (or alkalizing) agents were determined to be the dominant destabilizing factors. In wet granulations, basic agents, however, were found to suppress drug degradation even in the presence of moisture. Supported by the product distribution studies, the stabilization is proposed to involve the neutralization of the acidic drug by the basic excipients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2362911     DOI: 10.1023/a:1015871406549

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  4 in total

Review 1.  Recent developments in the design of angiotensin-converting enzyme inhibitors.

Authors:  M J Wyvratt; A A Patchett
Journal:  Med Res Rev       Date:  1985 Oct-Dec       Impact factor: 12.944

2.  Diketopiperazine formation, hydrolysis, and epimerization of the new dipeptide angiotensin-converting enzyme inhibitor RS-10085.

Authors:  L Gu; R G Strickley
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

Review 3.  Stability of solids and solid dosage forms.

Authors:  J T Carstensen
Journal:  J Pharm Sci       Date:  1974-01       Impact factor: 3.534

4.  Preformulation stability studies of the new dipeptide angiotensin-converting enzyme inhibitor RS-10029.

Authors:  L Gu; R G Strickley
Journal:  Pharm Res       Date:  1988-12       Impact factor: 4.200

  4 in total
  7 in total

1.  Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate.

Authors:  Jarrod W Collier; Rakhi B Shah; Abhay Gupta; Vilayat Sayeed; Muhammad J Habib; Mansoor A Khan
Journal:  AAPS PharmSciTech       Date:  2010-05-08       Impact factor: 3.246

Review 2.  Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.

Authors:  Yongmei Wu; Jaquan Levons; Ajit S Narang; Krishnaswamy Raghavan; Venkatramana M Rao
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

Review 3.  Impact of excipient interactions on solid dosage form stability.

Authors:  Ajit S Narang; Divyakant Desai; Sherif Badawy
Journal:  Pharm Res       Date:  2012-06-16       Impact factor: 4.200

4.  Ionization states in the microenvironment of solid dosage forms: effect of formulation variables and processing.

Authors:  Ramprakash Govindarajan; Andrey Zinchuk; Bruno Hancock; Evgenyi Shalaev; Raj Suryanarayanan
Journal:  Pharm Res       Date:  2006-08-24       Impact factor: 4.200

5.  Effect of carbonate salts on the kinetics of acid-catalyzed dimerization of adefovir dipivoxil.

Authors:  L C Yuan; T C Dahl; R Oliyai
Journal:  Pharm Res       Date:  2000-09       Impact factor: 4.200

6.  Physicomechanical characterization and optimization of EDTA-mPEG and Avicel®-EDTA-mPEG in situ melt dispersion mini-pellets.

Authors:  Angus R Hibbins; Yahya E Choonara; Pradeep Kumar; Lisa C du Toit; Viness Pillay
Journal:  AAPS PharmSciTech       Date:  2013-06-04       Impact factor: 3.246

7.  Compatibility study of rosmarinic acid with excipients used in pharmaceutical solid dosage forms using thermal and non-thermal techniques.

Authors:  Kleyton Santos Veras; Flávia Nathiely Silveira Fachel; Vanessa Pittol; Keth Ribeiro Garcia; Valquíria Linck Bassani; Venina Dos Santos; Amélia Teresinha Henriques; Helder Ferreira Teixeira; Letícia Scherer Koester
Journal:  Saudi Pharm J       Date:  2019-09-25       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.